Algorithme Pharma
Algorithme Pharma Holdings Inc. is a Canadian corporation specializing in clinical trials and bioanalysis including a wide range of services in bioequivalence and early stage development (Phase I/IIa) studies for the pharmaceutical and biotechnology industries. The corporation also supplies other types of services including protocol designs, CTD/ICH clinical reports, data management, biostatistics, quality assurance (QA) and regulatory affairs. The company was successfully audited by the US FDA, Canada TPD, Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES regulatory authorities.
Algorithme Pharma was founded in 1992 and is headquartered at 575, Armand-Frappier Blvd, Laval, Quebec, Canada in The Biotech City area.
With 500 employees, the company has facilities in Canada and the United Kingdom.
Location
Headquartered in Laval (Quebec, Canada), Algorithme Pharma’s multi-unit clinics and bioanalytical facilities are located in Montreal (Quebec, Canada) and Merthyr Tydfil (Wales, UK), and their medical laboratory is located in Merthyr Tydfil (Wales, UK).
Strategic Partnerships
- In March 2010, Algorithme Pharma announced the strategic appointment of Christopher Perkin as the company’s President and Chief Executive Officer
- In August 2008, Algorithme Pharma gained a foothold in Europe through the acquisition of a clinical research facility, Simbec Research Ltd, located in Merthyr Tydfil, Wales.
- In October 2007, Algorithme Pharma entered into a significant partnership with Kilmer Capital Partners, a leading Canadian investment group.
Regulatory Authorities
- Its Canadian facilities were successfully audited by the US FDA, Canada TPD, Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES regulatory authorities.
- Its United Kingdom facilities were successfully audited by MHRA-GMP, MHRA-GLP, MHRA-GCP, MHRA-Supplementary Accreditation Phase I, U.S. FDA, UK-College of Clinical Pathology Accreditation and Member of CCRA.
Services
- Bioavailability
- Bioequivalence
- Special Population
- First-in-human trials (FIHT), Phase I/IIa studies
- Definitive / Thorough QTc evaluations
- Food effects /[...]-[...] interactions / Age / Gender
- Dose Ranging
- [...] Interactions
- Pharmacodynamics
- Pharmacokinetics
- Single Ascending dose (SAD) and Multiple Dose (MAD)
- Dermatology
- Ophthalmology
- Cognitive Function
- Complex Integrated Protocol Designs
- Radio-labeled studies, including ADME, AMS and Microdosing
- Biomarkers
- Y-Scintigraphy
- LC-MS/MS
- Dried Blood Spot analysis
- Extremely low sensitivity assays development
- Emphasis on metabolite interference in incurred samples
- Endogenous compounds quantitation
- Different matrices [...] analysis (plasma, blood, urine, serum, feces, tissues, etc.)
- Pre-clinical and clinical samples analysis
- Multiple proprietary compounds analysis
- Quality Assurance
- Volunteer’s recruitment
See also
- The Biotech City at the BIO International Convention in Chicago citebiotech.com - 2010/05/19
- New CEOs: The first 100 days ngpharma.com
- Charles River Labs exec to bow out for Canadian CEO spot massdevice.com - 2010/03/23
- Algorithme Pharma : Rebondir malgré la crise LesAffaires.com - 2010/02/20
- Outsourcing M&A Year In Review contractpharma.com - 2009/02
- Platinum Club members Canada’s 50 Best Managed Companies
- Canada’s 50 Best Managed Companies Announced business.queensu.ca - 2007/02/07
- Études cliniques - Les médicaments au banc d'essai Ledevoir.com - 2005/09/17
- Companies in pre-clinical contractual research Montreal-invivo.com